Proxy Votes Now

Home › Activist investors › Nantahala Capital

Nantahala Capital

Other large holder. Positions and campaigns from Nantahala Capital’s SEC filings. Updated November 20, 2026.

Filer entities
Nantahala Capital Management, LLC
SEC CIK
1472322 (Nantahala Capital Management, LLC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 13, 2026: 142 US-listed positions reported; 83 of 1% or more of a company without a 13D are listed below.
88current positions
83new or changed in 90 days; 7 exited
0active campaigns
0campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (88)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Altisource Portfolio Solutions SA 43.34%4,954,624 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 23, 2026 Nov 14, 2023 Decreased Nov 13, 2026 — Decreased 13F: none stated
Aeon Biopharma Inc. 16.73%4,400,000 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 11, 2026 Nov 13, 2026 — — New 13F: none stated
TELA Bio, Inc. 14.58%6,545,596 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026 Nov 10, 2022 Decreased Nov 13, 2026 ▼ 11.68 pts Decreased 13F: none stated
Dariohealth Corp. 9.98%978,340 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Feb 14, 2019 Decreased Nov 13, 2026 ▼ 2.48 pts Decreased 13F: none stated
Eloxx Pharmaceuticals, Inc. 9.91%400,000 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 7, 2026 Aug 16, 2021 Decreased Nov 13, 2026 ▼ 9.91 pts Decreased 13F: none stated
ADC Therapeutics SA 9.85%12,576,184 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 3, 2026 Feb 14, 2023 Decreased Nov 13, 2026 ▼ 9.46 pts Decreased 13F: none stated
Bioventus Inc. 9.54%6,420,884 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 28, 2026 Nov 10, 2022 Decreased Nov 13, 2026 ▼ 8.29 pts Decreased 13F: none stated
Abeona Therapeutics Inc. 9.46%5,410,643 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026 Feb 14, 2023 Decreased Nov 13, 2026 ▼ 8.50 pts Decreased 13F: none stated
Evolus Inc. 9.43%6,244,690 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Nov 14, 2023 Decreased Nov 13, 2026 ▼ 7.53 pts Decreased 13F: none stated
The Hain Celestial Group, Inc. 9.37%8,528,789 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 20, 2026 Aug 14, 2025 Decreased Nov 13, 2026 ▼ 9.53 pts Decreased 13F: none stated
Fossil Group, Inc. 9.31%5,505,128 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026 Aug 14, 2023 Decreased Nov 13, 2026 ▼ 9.31 pts Decreased 13F: none stated
Noodles & Company 9.29%554,246 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 21, 2026 Aug 14, 2023 Decreased Nov 13, 2026 ▼ 9.27 pts Decreased 13F: none stated
Jack in the Box Inc. 9.02%1,730,659 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026 Aug 14, 2025 Decreased Nov 13, 2026 ▼ 9.00 pts Decreased 13F: none stated
Fulcrum Therapeutics, Inc. 8.62%6,575,352 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 23, 2026 Feb 14, 2023 Decreased Nov 13, 2026 ▼ 5.73 pts Decreased 13F: none stated
Destination XL Group, Inc. 8.40%4,658,915 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Sep 3, 2026 Aug 14, 2025 Decreased Nov 13, 2026 ▼ 6.58 pts Decreased 13F: none stated
Gogo Inc. 8.27%11,214,792 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Nov 14, 2024 Decreased Nov 13, 2026 ▼ 4.57 pts Decreased 13F: none stated
Apyx Medical Corporation 7.94%3,343,353 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 4, 2026 Feb 14, 2025 Decreased Nov 13, 2026 ▼ 7.59 pts Decreased 13F: none stated
Keros Therapeutics, Inc. 7.59%1,490,051 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2020 Decreased Nov 13, 2026 ▼ 6.63 pts Decreased 13F: none stated
Elutia Inc. 7.41%3,184,947 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026 Nov 14, 2023 Decreased Nov 13, 2026 ▼ 7.41 pts Decreased 13F: none stated
InspireMD, Inc. 7.26%3,376,484 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 14, 2026 Aug 14, 2023 Decreased Nov 13, 2026 ▼ 7.26 pts Decreased 13F: none stated
The ONE Group Hospitality, Inc. 6.70%2,139,182 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 31, 2026 May 15, 2024 Decreased Nov 13, 2026 ▼ 6.69 pts Decreased 13F: none stated
DHI Group, Inc. 5.87%2,491,945 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 May 15, 2018 Decreased Nov 13, 2026 ▼ 5.07 pts Decreased 13F: none stated
Opus Genetics, Inc. 5.49%4,569,528 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 3, 2026 May 15, 2025 Decreased Nov 13, 2026 ▼ 1.87 pts Decreased 13F: none stated
eHealth, Inc. 5.44%1,761,441 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2020 Decreased Nov 13, 2026 ▼ 5.55 pts Decreased 13F: none stated
USANA Health Sciences, Inc. 5.35%988,543 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Feb 13, 2026 Decreased Nov 13, 2026 ▼ 3.42 pts Decreased 13F: none stated
Unicycive Therapeutics Inc. 5.03%1,401,448 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026 Nov 15, 2021 Decreased Nov 13, 2026 ▼ 5.03 pts Decreased 13F: none stated
Titan Machinery Inc. 4.83%1,137,589 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 31, 2026 Nov 14, 2024 Decreased Nov 13, 2026 ▼ 4.89 pts Decreased 13F: none stated
Benitec Biopharma Inc. 4.81%1,677,567 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Sep 4, 2026 Aug 14, 2024 Decreased Nov 13, 2026 ▼ 3.86 pts Decreased 13F: none stated
MiMedx Group, Inc. 4.74%6,910,564 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 22, 2026 Feb 14, 2023 Decreased Nov 13, 2026 ▼ 1.81 pts Decreased 13F: none stated
Korro Bio, Inc. 4.72%680,246 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 4, 2026 Feb 13, 2026 Decreased Nov 13, 2026 ▼ 4.44 pts Decreased 13F: none stated
Fractyl Health, Inc. 4.70%7,458,269 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 1, 2026 Nov 14, 2025 Decreased Nov 13, 2026 ▼ 9.53 pts Decreased 13F: none stated
Curis, Inc. 4.49%93,824 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Feb 16, 2021 Decreased Nov 13, 2026 — Decreased 13F: none stated
Passage Bio Inc. 3.96%127,370 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026 Nov 13, 2026 — — New 13F: none stated
Traeger, Inc. 3.93%109,266 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 7, 2026 May 15, 2026 Decreased Nov 13, 2026 ▼ 2.03 pts Decreased 13F: none stated
Gaia, Inc. 3.90%974,138 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026 May 15, 2018 Decreased Nov 13, 2026 ▼ 3.42 pts Decreased 13F: none stated
Avalo Therapeutics, Inc. 3.70%2,142,308 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 Nov 15, 2021 Decreased Nov 13, 2026 ▼ 3.24 pts Decreased 13F: none stated
Aura Biosciences, Inc. 3.67%3,807,300 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026 Feb 14, 2022 Decreased Nov 13, 2026 ▼ 2.02 pts Decreased 13F: none stated
The Bancorp, Inc. 3.67%1,465,277 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2014 Decreased Nov 13, 2026 ▼ 2.41 pts Decreased 13F: none stated
Azitra Inc. 3.65%2,213,613 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 3.65 pts Decreased 13F: none stated
Savara Inc. 3.47%7,137,159 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Nov 14, 2023 Decreased Nov 13, 2026 ▼ 3.32 pts Decreased 13F: none stated
Fox Factory Holding Corp. 3.35%1,403,584 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Apr 3, 2026 Feb 14, 2025 Decreased Nov 13, 2026 ▼ 2.90 pts Decreased 13F: none stated
LB Pharmaceuticals Inc 3.32%1,074,374 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 3, 2026 Nov 14, 2025 Decreased Nov 13, 2026 ▼ 3.21 pts Decreased 13F: none stated
Rayonier Advanced Materials Inc. 3.31%2,236,017 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 May 16, 2016 Decreased Nov 13, 2026 ▼ 1.71 pts Decreased 13F: none stated
Zevra Therapeutics Inc 3.30%1,963,096 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Nov 14, 2023 Decreased Nov 13, 2026 ▼ 2.75 pts Decreased 13F: none stated
Eton Pharmaceuticals, Inc. 3.20%875,507 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 12, 2026 Aug 14, 2024 Decreased Nov 13, 2026 ▼ 5.39 pts Decreased 13F: none stated
Alector, Inc. 2.90%4,318,109 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 May 13, 2022 Decreased Nov 13, 2026 ▼ 4.83 pts Decreased 13F: none stated
JATT II Acquisition Corp. 2.88%225,000 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 2.72 pts Decreased 13F: none stated
Anteris Technologies Global Corp. 2.83%2,759,807 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026 Feb 14, 2025 Decreased Nov 13, 2026 ▼ 4.11 pts Decreased 13F: none stated
JATT III Acquisition Corp 2.82%250,000 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 12, 2026 Nov 13, 2026 — — New 13F: none stated
Venu Holding Corp. 2.75%1,546,705 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 13, 2026 May 15, 2026 Decreased Nov 13, 2026 ▼ 2.75 pts Decreased 13F: none stated
Alta Equipment Group Inc. 2.42%791,839 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 4, 2026 May 14, 2020 Decreased Nov 13, 2026 ▼ 2.01 pts Decreased 13F: none stated
X4 Pharmaceuticals Inc. 2.40%2,449,468 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 Nov 14, 2025 Decreased Nov 13, 2026 ▼ 2.54 pts Decreased 13F: none stated
Codexis, Inc. 2.37%2,597,869 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026 May 15, 2014 Decreased Nov 13, 2026 ▼ 4.25 pts Decreased 13F: none stated
Cellectar Biosciences Inc. 2.33%219,998 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026 Feb 14, 2024 Decreased Nov 13, 2026 ▼ 2.33 pts Decreased 13F: none stated
Ultragenyx Pharmaceutical Inc. 2.30%2,339,293 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 29, 2026 Nov 13, 2026 — — New 13F: none stated
Grace Therapeutics, Inc. 2.26%476,190 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 11, 2026 Nov 13, 2026 — — New 13F: none stated
Perspective Therapeutics, Inc. 2.18%2,492,642 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 1.89 pts Decreased 13F: none stated
Geron Corporation 2.15%13,873,533 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Nov 14, 2025 Decreased Nov 13, 2026 ▼ 1.65 pts Decreased 13F: none stated
Forrester Research, Inc. 2.13%413,046 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 4, 2026 May 15, 2026 Decreased Nov 13, 2026 ▼ 5.74 pts Decreased 13F: none stated
Viemed Healthcare, Inc. 1.89%714,674 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 27, 2026 Nov 14, 2019 Decreased Nov 13, 2026 ▼ 1.43 pts Decreased 13F: none stated
Immunic, Inc. 1.84%250,646 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 31, 2026 Feb 13, 2026 Decreased Nov 13, 2026 ▼ 1.84 pts Decreased 13F: none stated
Herbalife LTD. 1.76%1,847,165 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026 May 15, 2025 Decreased Nov 13, 2026 ▼ 0.36 pts Decreased 13F: none stated
Entera Bio Ltd. 1.73%3,004,848 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 Nov 13, 2026 — — New 13F: none stated
Hilton Grand Vacations Inc. 1.68%1,276,542 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 22, 2026 Feb 14, 2023 Decreased Nov 13, 2026 ▼ 0.97 pts Decreased 13F: none stated
Aprea Therapeutics, Inc. 1.66%205,760 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 13, 2026 May 15, 2024 Decreased Nov 13, 2026 ▼ 1.66 pts Decreased 13F: none stated
Lexeo Therapeutics, Inc. 1.66%1,300,000 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 7, 2026 Feb 13, 2026 Decreased Nov 13, 2026 ▼ 1.66 pts Decreased 13F: none stated
Distribution Solutions Group, Inc. 1.58%733,684 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 31, 2026 Aug 14, 2025 Decreased Nov 13, 2026 ▼ 0.55 pts Decreased 13F: none stated
Vor Biopharma Inc. 1.52%931,644 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 1.34 pts Decreased 13F: none stated
Inhibikase Therapeutics, Inc. 1.48%1,951,863 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 1, 2026 Feb 14, 2025 Decreased Nov 13, 2026 ▼ 2.61 pts Decreased 13F: none stated
Establishment Labs Holdings Inc. 1.48%440,556 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 5, 2026 Nov 14, 2018 Decreased Nov 13, 2026 ▼ 0.78 pts Decreased 13F: none stated
Vyne Therapeutics Inc. 1.47%39,198 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026 Feb 13, 2026 Decreased Nov 13, 2026 — Decreased 13F: none stated
Sagimet Biosciences Inc. 1.45%471,831 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026 Nov 13, 2026 — — New 13F: none stated
Reservoir Media, Inc. 1.44%952,955 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026 Nov 14, 2023 Decreased Nov 13, 2026 ▼ 1.41 pts Decreased 13F: none stated
Jefferson Capital, Inc. 1.44%825,607 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 13, 2026 Aug 14, 2025 Decreased Nov 13, 2026 ▼ 1.17 pts Decreased 13F: none stated
Verastem, Inc. 1.41%1,779,840 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 Aug 14, 2024 Decreased Nov 13, 2026 ▼ 6.50 pts Decreased 13F: none stated
Janux Therapeutics, Inc. 1.40%857,334 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 3, 2026 May 15, 2026 Decreased Nov 13, 2026 ▼ 1.25 pts Decreased 13F: none stated
Cue Biopharma, Inc. 1.32%96,049 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026 Nov 13, 2026 — — New 13F: none stated
Industrial Logistics Properties Trust 1.31%876,153 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026 May 15, 2023 Decreased Nov 13, 2026 ▼ 2.02 pts Decreased 13F: none stated
Attovia Therapeutics, Inc. 1.23%561,180 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 31, 2026 Nov 13, 2026 — — New 13F: none stated
ADMA Biologics, Inc. 1.17%2,590,475 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 0.94 pts Decreased 13F: none stated
Lisata Therapeutics, Inc. 1.12%101,221 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026 Nov 13, 2026 — — New 13F: none stated
Service Properties Trust 1.07%1,386,791 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026 Feb 14, 2025 Decreased Nov 13, 2026 ▼ 3.04 pts Decreased 13F: none stated
Inspire Medical Systems, Inc. 1.01%293,034 shares 13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 28, 2026 Aug 14, 2026 Decreased Nov 13, 2026 ▼ 0.85 pts Decreased 13F: none stated
Xtant Medical Holdings, Inc. 49.1%68,394,000 shares Schedule 13D/A, filed Aug 5, 2025 Apr 17, 2025 — 0.00 pts — Standard Item 4 language
Aytu Biopharma, Inc 14.4%1,086,812 shares Schedule 13D/A, filed Jun 9, 2025 Jun 16, 2023 — ▼ 3.80 pts — Standard Item 4 language
Talphera, Inc. 11.7%1,992,519 shares Schedule 13D/A, filed Apr 3, 2025 Jan 23, 2024 — 0.00 pts — Standard Item 4 language
Femasys Inc. 10.0%803,038 shares Schedule 13D, filed Aug 17, 2026 Aug 17, 2026 — — — Standard Item 4 language
America'S Car-Mart, Inc. 7.8%644,686 shares Schedule 13D/A, filed Mar 12, 2025 Sep 24, 2024 Increased Mar 12, 2025 ▲ 1.10 pts — Standard Item 4 language

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Xtant Medical Holdings, Inc. · Standard Item 4 language

“Item 4 is amended by the addition of the following: On August 1, 2025, the Board of Directors (the "Board") of the Issuer elected Abhinav (Abi) Jain, an Analyst at NCM, to the Board. Mr. Jain was appointed to serve as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board. Mr. Jain's appointment was described further by the Issuer in a Form 8-K filed”

Item 4 in the Schedule 13D/A filed Aug 5, 2025.

Aytu Biopharma, Inc · Standard Item 4 language

“Item 4 is amended by the addition of the following: On June 6, 2025, the Reporting Persons caused the Nantahala Investors to purchase prefunded warrants (the "June 2025 Prefunded Warrants") in an underwritten offering (the "June 2025 Offering") by the Issuer. Using cash on hand, the Nantahala Investors purchased June 2025 Prefunded Warrants exercisable, subject to the terms and conditions thereof,”

Item 4 in the Schedule 13D/A filed Jun 9, 2025.

Talphera, Inc. · Standard Item 4 language

“Item 4 is hereby amended by the addition of the following: The Nantahala Investors made the March 2025 Warrant Purchase described above in Item 3 based on the Reporting Persons' belief that the Common Stock was undervalued and represented an attractive investment opportunity. In the SPA, the Nantahala Investors committed to make (i) a further investment of the same size in a second closing upon the…”

Item 4 in the Schedule 13D/A filed Apr 3, 2025; this amendment did not restate Item 4, so the text is from the filing of Apr 2, 2025.

Femasys Inc. · Standard Item 4 language

“The disclosure regarding the SPA and the Purchase set forth above in Item 3 is incorporated herein by reference. The Issuer has further described the SPA, the Purchase and the Side Letter in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on August 14, 2026. Pursuant to a side letter (the "Side Letter") entered into by Nantahala and the Issuer on August…”

Item 4 in the Schedule 13D filed Aug 17, 2026.

Summary of the filing Nantahala Capital's August 2026 stock purchase and side letter with FEMASYS grants it board seats and consent rights over major corporate actions, including CEO removal and new debt.

Quoted from the filing (item 4): “The Issuer also agreed to use its commercially reasonable efforts to facilitate the voluntary resignation of two current members of the Board within sixty days after the Purchase” Aug 17, 2026

America'S Car-Mart, Inc. · Standard Item 4 language

“The Reporting Persons caused the Nantahala Investors to make the investments described above in Item 3 for ordinary investment purposes. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or…”

Item 4 in the Schedule 13D/A filed Mar 12, 2025; this amendment did not restate Item 4, so the text is from the filing of Sep 24, 2024.

Past positions (8)
CompanyLast stakeSourceOutcomeDate
ALX Oncology Holdings Inc. 1.08% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 30, 2026 Not in the latest 13F Nov 13, 2026
Entrada Therapeutics, Inc. 1.55% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Apr 30, 2026 Not in the latest 13F Nov 13, 2026
Rallybio Corp. 7.10% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 30, 2026 Not in the latest 13F Nov 13, 2026
SPAR Group, Inc. 4.65% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Aug 6, 2026 Not in the latest 13F Nov 13, 2026
Senti Biosciences, Inc. 2.85% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 Not in the latest 13F Nov 13, 2026
Guardforce AI Co. LTD. 1.27% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Dec 31, 2025 Not in the latest 13F Nov 13, 2026
uniQure N.V. 1.31% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 24, 2026 Not in the latest 13F Nov 13, 2026
Evoke Pharma Inc 0.0% Schedule 13D/A, filed Dec 19, 2025 Exited Dec 19, 2025

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Nantahala Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Passage Bio Inc. · Nantahala Capital first disclosed Nov 13, 2026 · 1 other filing
HolderFormDateStake
Lynx1 Capital Management LP Schedule 13D Jul 2, 2026 21.0%
Ultragenyx Pharmaceutical Inc. · Nantahala Capital first disclosed Nov 13, 2026 · 6 other filings
HolderFormDateStake
BlackRock, Inc. Schedule 13G Jul 30, 2026 8.3%
Vanguard Capital Management Schedule 13G Jul 31, 2026 5.1%
Vanguard Portfolio Management Schedule 13G Jul 31, 2026 7.0%
State Street Corporation Schedule 13G Aug 7, 2026 6.3%
AQR Capital Management, LLC Schedule 13G Aug 13, 2026 6.7%
RTW Investments, LP Schedule 13G Aug 14, 2026 7.9%
Entera Bio Ltd. · Nantahala Capital first disclosed Nov 13, 2026 · 2 other filings
HolderFormDateStake
Biotechnology Value Fund L P Schedule 13D Aug 4, 2026 10.0%
Ra Capital Management, L.P. 13F Nov 16, 2026 2.8%
Attovia Therapeutics, Inc. · Nantahala Capital first disclosed Nov 13, 2026 · 1 other filing
HolderFormDateStake
Frazier Life Sciences Public Fund, L.P. Schedule 13D Aug 11, 2026 13.5%
Sagimet Biosciences Inc. · Nantahala Capital first disclosed Nov 13, 2026 · 2 other filings
HolderFormDateStake
Caligan Partners 13F Aug 14, 2026 8.6%
Ra Capital Management, L.P. 13F Nov 16, 2026 5.5%
Cue Biopharma, Inc. · Nantahala Capital first disclosed Nov 13, 2026 · 1 other filing
HolderFormDateStake
Shao-Lee Lin Schedule 13D Aug 21, 2026 6.2%
JATT III Acquisition Corp · Nantahala Capital first disclosed Nov 13, 2026 · 2 other filings
HolderFormDateStake
JATT Ventures III L.P. Schedule 13D Sep 3, 2026 22.1%
Ra Capital Management, L.P. 13F Nov 16, 2026 5.1%
Inspire Medical Systems, Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 9 other filings
HolderFormDateStake
Kenneth Griffin Schedule 13G Feb 17, 2026 1.8%
Vanguard Portfolio Management Schedule 13G Apr 29, 2026 5.7%
Vanguard Capital Management Schedule 13G Apr 30, 2026 5.1%
Deerfield Mgmt, L.P. Schedule 13G May 14, 2026 4.5%
Wellington Management Group LLP Schedule 13G May 15, 2026 8.8%
Soleus Capital Master Fund, L.P. Schedule 13G May 27, 2026 5.1%
D. E. Shaw & Co., L.P. Schedule 13G Jul 2, 2026 5.1%
BlackRock, Inc. Schedule 13G Jul 28, 2026 14.4%
AQR Capital Management, LLC Schedule 13G Aug 12, 2026 6.4%
Vor Biopharma Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 1 other filing
HolderFormDateStake
Caligan Partners 13F Feb 17, 2026 3.1%
Perspective Therapeutics, Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 5 other filings
HolderFormDateStake
Avidity Partners Management LP Schedule 13G Mar 10, 2026 5.3%
BlackRock, Inc. Schedule 13G Apr 27, 2026 4.6%
Morgan Stanley Schedule 13G May 12, 2026 2.6%
Millennium Management LLC Schedule 13G Jun 30, 2026 4.3%
State Street Corporation Schedule 13G Aug 7, 2026 5.3%
ADMA Biologics, Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 3 other filings
HolderFormDateStake
Vanguard Capital Management Schedule 13G Apr 29, 2026 5.1%
Rubric Capital 13F May 15, 2026 5.6%
State Street Corporation Schedule 13G Aug 7, 2026 7.4%
ALX Oncology Holdings Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 1 other filing
HolderFormDateStake
Ra Capital Management, L.P. 13F May 15, 2026 9.4%
Azitra Inc. · Nantahala Capital first disclosed Aug 14, 2026 · 2 other filings
HolderFormDateStake
Salva Francisco D. Schedule 13D Jun 24, 2026 10.0%
Young Pharmaceuticals, Inc. Schedule 13D Nov 16, 2026 5.2%
JATT II Acquisition Corp. · Nantahala Capital first disclosed Aug 14, 2026 · 2 other filings
HolderFormDateStake
Ra Capital Management, L.P. 13F Aug 14, 2026 6.4%
JATT Ventures II L.P. Schedule 13D Sep 15, 2026 23.1%
Janux Therapeutics, Inc. · Nantahala Capital first disclosed May 15, 2026 · 7 other filings
HolderFormDateStake
FMR LLC Schedule 13G Jan 8, 2026 5.8%
Prosight Management, LP Schedule 13G Feb 6, 2026 5.2%
State Street Corporation Schedule 13G Feb 9, 2026 6.4%
Janus Henderson Group PLC Schedule 13G Feb 17, 2026 8.9%
Point72 Asset Management, L.P. Schedule 13G Apr 29, 2026 5.0%
BlackRock, Inc. Schedule 13G Jul 28, 2026 6.7%
JANUS HENDERSON GROUP Ltd. Schedule 13G Aug 13, 2026 0.3%
Forrester Research, Inc. · Nantahala Capital first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
Portolan Capital Management, LLC Schedule 13G Feb 19, 2026 6.1%
Venu Holding Corp. · Nantahala Capital first disclosed May 15, 2026 · 1 other filing
HolderFormDateStake
Anson Funds 13F May 14, 2026 8.6%
USANA Health Sciences, Inc. · Nantahala Capital first disclosed Feb 13, 2026 · 3 other filings
HolderFormDateStake
Dimensional Fund Advisors LP Schedule 13G Oct 9, 2025 5.0%
Pzena Investment Management LLC Schedule 13G Oct 14, 2025 6.6%
BlackRock, Inc. Schedule 13G Jan 21, 2026 4.4%
Korro Bio, Inc. · Nantahala Capital first disclosed Feb 13, 2026 · 8 other filings
HolderFormDateStake
Driehaus Capital Management LLC Schedule 13G Nov 14, 2025 7.2%
Lynx1 Capital Management LP Schedule 13G Jan 5, 2026 7.8%
The Vanguard Group Schedule 13G Jan 30, 2026 5.2%
FMR LLC Schedule 13G Feb 5, 2026 0.4%
Point72 Biotech Private Investments, LLC Schedule 13G Feb 17, 2026 2.9%
Steven A. Cohen Schedule 13G Mar 11, 2026 5.7%
Venrock Healthcare Capital Partners III, L.P. Schedule 13G Mar 17, 2026 9.9%
BlackRock, Inc. Schedule 13G Jul 29, 2026 5.2%
Immunic, Inc. · Nantahala Capital first disclosed Feb 13, 2026 · 1 other filing
HolderFormDateStake
Biotechnology Value Fund L P Schedule 13D Feb 20, 2026 10.0%
Vyne Therapeutics Inc. · Nantahala Capital first disclosed Feb 13, 2026 · 1 other filing
HolderFormDateStake
Orbimed Advisors LLC Schedule 13D Aug 5, 2026 10.0%
X4 Pharmaceuticals Inc. · Nantahala Capital first disclosed Nov 14, 2025 · 2 other filings
HolderFormDateStake
Bain Capital Life Sciences Fund, L.P. Schedule 13D Aug 13, 2025 10.0%
Coastlands Capital LP Schedule 13D Aug 18, 2025 10.0%
Geron Corporation · Nantahala Capital first disclosed Nov 14, 2025 · 2 other filings
HolderFormDateStake
Deep Track Capital, LP Schedule 13G Aug 14, 2025 6.8%
Soleus Capital Master Fund, L.P. Schedule 13G Mar 3, 2026 5.2%
LB Pharmaceuticals Inc · Nantahala Capital first disclosed Nov 14, 2025 · 3 other filings
HolderFormDateStake
Deep Track Biotechnology Master Fund, Ltd. Schedule 13D Sep 19, 2025 14.9%
Pontifax Management 4 G.P. (2015) Ltd. Schedule 13D Sep 25, 2025 6.3%
Ra Capital Management, L.P. 13F Nov 14, 2025 6.8%
The Hain Celestial Group, Inc. · Nantahala Capital first disclosed Aug 14, 2025 · 6 other filings
HolderFormDateStake
Millennium Management LLC Schedule 13G Mar 26, 2025 5.2%
BlackRock, Inc. Schedule 13G Apr 3, 2025 7.4%
The Vanguard Group Schedule 13G Apr 30, 2025 9.3%
Barrow Hanley Mewhinney & Strauss LLC Schedule 13G May 14, 2025 7.0%
Invesco Ltd. Schedule 13G Aug 7, 2025 0.3%
Neuberger Berman Group LLC Schedule 13G Oct 14, 2025 5.1%
Jack in the Box Inc. · Nantahala Capital first disclosed Aug 14, 2025 · 7 other filings
HolderFormDateStake
LSV Asset Management Schedule 13G May 1, 2025 5.3%
Biglari Capital Schedule 13D Jul 10, 2025 10.0%
BlackRock, Inc. Schedule 13G Jul 17, 2025 14.5%
The Vanguard Group Schedule 13G Jul 29, 2025 8.5%
Green Frog Investments Inc Schedule 13G Aug 13, 2025 5.0%
Callodine Capital Management, LP Schedule 13G Aug 14, 2025 8.6%
GreenWood Investors LLC Schedule 13D Nov 18, 2025 6.1%
Destination XL Group, Inc. · Nantahala Capital first disclosed Aug 14, 2025 · 4 other filings
HolderFormDateStake
Wolf Hill Capital Management, LP Schedule 13G May 14, 2025 2.7%
BlackRock, Inc. Schedule 13G Jul 17, 2025 1.6%
The Vanguard Group Schedule 13G Jul 29, 2025 4.7%
Nomura Holdings Inc Schedule 13G Nov 14, 2025 4.0%
Herbalife LTD. · Nantahala Capital first disclosed May 15, 2025 · 5 other filings
HolderFormDateStake
Long Focus Capital Management, LLC Schedule 13G Feb 5, 2025 5.0%
Route One Investment Company, L.P. Schedule 13G Feb 13, 2025 4.1%
Renaissance Technologies LLC Schedule 13G Feb 13, 2025 7.0%
Baupost Group Llc/Ma Schedule 13G Feb 13, 2025 8.5%
The Vanguard Group Schedule 13G Apr 30, 2025 12.3%
Service Properties Trust · Nantahala Capital first disclosed Feb 14, 2025 · 4 other filings
HolderFormDateStake
BlackRock, Inc. Schedule 13G Jan 8, 2025 9.6%
The Vanguard Group Schedule 13G Jan 31, 2025 12.0%
State Street Corporation Schedule 13G Feb 5, 2025 3.1%
Charles Schwab Investment Management Inc Schedule 13G Aug 11, 2025 5.0%
Fox Factory Holding Corp. · Nantahala Capital first disclosed Feb 14, 2025 · 4 other filings
HolderFormDateStake
William Blair Investment Management, LLC Schedule 13G Feb 12, 2025 7.2%
Kayne Anderson Rudnick Investment Management, LLC Schedule 13G Feb 13, 2025 4.3%
RWWM, Inc. Schedule 13G Apr 25, 2025 8.6%
BlackRock, Inc. Schedule 13G Apr 30, 2025 15.0%
Gogo Inc. · Nantahala Capital first disclosed Nov 14, 2024 · 1 other filing
HolderFormDateStake
FMR LLC Schedule 13G Jan 8, 2025 10.3%
America'S Car-Mart, Inc. · Nantahala Capital first disclosed Sep 24, 2024 · 2 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Jan 30, 2025 5.2%
FMR LLC Schedule 13G Feb 12, 2025 5.4%
Benitec Biopharma Inc. · Nantahala Capital first disclosed Aug 14, 2024 · 1 other filing
HolderFormDateStake
Suvretta Capital Management, LLC Schedule 13D Apr 29, 2024 20.0%
Verastem, Inc. · Nantahala Capital first disclosed Aug 14, 2024 · 2 other filings
HolderFormDateStake
AIGH Capital Management LLC Schedule 13G Jan 21, 2025 6.1%
The Vanguard Group Schedule 13G Jan 31, 2025 5.2%
The ONE Group Hospitality, Inc. · Nantahala Capital first disclosed May 15, 2024 · 1 other filing
HolderFormDateStake
Hill Path Capital LP Schedule 13D May 8, 2024 8.2%
Reservoir Media, Inc. · Nantahala Capital first disclosed Nov 14, 2023 · 1 other filing
HolderFormDateStake
Irenic Capital Schedule 13D Dec 20, 2023 9.3%
Noodles & Company · Nantahala Capital first disclosed Aug 14, 2023 · 2 other filings
HolderFormDateStake
Mill Road Capital Schedule 13D Jun 1, 2023 14.7%
Hoak Public Equities, LP Schedule 13D Jun 23, 2023 5.2%
InspireMD, Inc. · Nantahala Capital first disclosed Aug 14, 2023 · 1 other filing
HolderFormDateStake
Shore Craig Schedule 13D Jun 16, 2023 8.0%
Industrial Logistics Properties Trust · Nantahala Capital first disclosed May 15, 2023 · 1 other filing
HolderFormDateStake
Stone House Capital Management, LLC Schedule 13D Aug 31, 2023 5.3%
MiMedx Group, Inc. · Nantahala Capital first disclosed Feb 14, 2023 · 1 other filing
HolderFormDateStake
Cannell Capital 13F May 15, 2023 1.3%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.